drugset
drugset / Trial / NCT05909215

Attenuation Of Hemodynamic Response To Laryngoscopy. Role Of Dexmedetomidine. A Dose Finding Study

NCT05909215 ↗

Phase 4 Completed 105 enrolled Sindh Institute of Urology and Transplantation
RandomizedParallel-groupDouble-blindTreatment

Summary

Two doses of Dexmedetomidine (0.5 µ/kg and 0.75 µ/kg) will be used to attenuate the stress response to laryngoscopy in American Society of Anesthesiology, physical class I patients which will be compared with the placebo-controlled group.

Timeline

Start
2021-08-23
Primary completion
2021-12-13
Completion
2021-12-13

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dexmedetomidine Other / unclassified 0.5 ug/kg Intravenous
Comparator Dexmedetomidine Other / unclassified 0.75 ug/kg Intravenous

Indications

No indication recorded.